https://www.selleckchem.com/pr....oducts/bay-1161909.h
mapped volumes of interest, deformed and cumulative doses than results based on conventional FDK_CBCT. To show pharmacokinetic (PK) and pharmacodynamic (PD) bioequivalence between Myxredlin, a novel, ready-to-use regular human insulin 1U/mL formulation (BAX-HI), and Novolin R 100 U/mL concentrate diluted to 1U/mL (NOVO-HI). This phase 1, double-blind, randomized, two-way crossover study compared the PK and PD properties of BAX-HI and NOVO-HI. A total of 58 healthy males received 0.36 U/kg of each study drug, administered intravenous
Curtir
Comentario
Compartilhar
